News

Tailored Rituxan Regimen for ANCA Vasculitis Patients as Effective, Possibly Safer than Fixed-schedule Treatment, Expert Says

An individually tailored treatment with Rituxan (rituximab) is as effective as the standard fixed-schedule regimen in preventing relapses over 28 months in ANCA-associated vasculitis (AAV) patients in remission. The data also indicated that the less frequent infusions in the tailored approach may improve safety, according to a…

Minimal Glucocorticoid Regimen Shows Similar Efficacy, Fewer Adverse Events than Standard Treatments, Study Reports

Patients with ANCA-associated vasculitis (AAV) who receive a minimal glucocorticoid treatment along with Rituxan (rituximab) and cyclophosphamide show similar improvement as those given standard glucocorticoid regimens, but have lower glucocorticoid-associated adverse events, a study shows. The study, “A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis,” was published…